Global Schizophrenia Therapeutics Market 2014-2018: Key Vendors are AstraZeneca, Bristol-Myers Squibb, Eli Lily, F. Hoffmann-La Roche, H. Lundbeck, Johnson & Johnson and Pfizer

News provided by

Dec 18, 2014, 12:45 ET

DUBLIN, Dec. 18, 2014 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/97slvx/global) has announced the addition of the "Global Schizophrenia Therapeutics Market 2014-2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help.

The analysts forecast the Global Schizophrenia Therapeutics market to grow at a CAGR of 2.82 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Schizophrenia Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of schizophrenia that are available in the market. The Global Schizophrenia Therapeutics market can be segmented into two: First-generation Antipsychotics and Second-generation Antipsychotics.

The report, the Global Schizophrenia Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Schizophrenia Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

One major trend in this market is the increase in the awareness of schizophrenia. The awareness among patients and physicians is expected to increase the penetration of drugs in the market.

According to the report, an increase in the aging population worldwide is one of the main drivers of the market. Aging is one of the main causes of CNS disorders, including schizophrenia. Therefore, the global burden of the disorder is increasing because of the rapidly aging population in different parts of the world.

Further, the report states that an increase in the generic competition is one of the main challenges that the market confronts. The availability of low-cost generic drugs intensifies the competition among the vendors and thus substantially reduces the cost of patented/branded drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

09. Types of Schizophrenia

10. Phases of Schizophrenia

11. Market Segmentation by Drug Class

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

21. Key Vendor Analysis

22. Other Reports in this Series

Companies Mentioned: